Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.

Lancet Infect Dis

Genetics, Vaccines, and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain; Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago (SERGAS), Santiago de Compostela, Spain. Electronic address:

Published: August 2024

AI Article Synopsis

  • Galicia, Spain, launched a program in September 2023 to give nirsevimab for RSV prevention in infants, focusing on newborns, those under 6 months, and high-risk children aged 6-24 months.
  • The interim analysis of the study, using data from Sept 25 to Dec 31, 2023, assesses nirsevimab's effectiveness in preventing different levels of RSV-related hospitalizations and complications.
  • The study compares the results with data from previous RSV seasons to calculate how many cases of hospitalization were potentially avoided due to the immunization campaign.

Article Abstract

Background: Galicia (Spain) was one of the first regions worldwide to incorporate nirsevimab for universal respiratory syncytial virus (RSV) prophylaxis in infants into its immunisation programme. The NIRSE-GAL longitudinal population-based study aimed to assess nirsevimab effectiveness in preventing hospitalisations (ie, admittance to hospital).

Methods: The 2023-24 immunisation campaign with nirsevimab in Galicia began on Sept 25, 2023, and concluded on March 31, 2024. The campaign targeted three groups: infants born during the campaign (seasonal group), infants younger than 6 months at the start of the campaign (catch-up group), and infants aged 6-24 months with high-risk factors at the start of the campaign (high-risk group). Infants in the seasonal group were offered immunisation on the first day of life before discharge from hospital. Infants in the catch-up and high-risk groups received electronic appointments to attend a public hospital or health-care centre for nirsevimab administration. For this interim analysis, we used data collected from Sept 25 to Dec 31, 2023, from children born up to Dec 15, 2023. Data were retrieved from public health registries. Nirsevimab effectiveness in preventing RSV-associated lower respiratory tract infection (LRTI) hospitalisations; severe RSV-related LRTI requiring intensive care unit admission, mechanical ventilation, or oxygen support; all-cause LRTI hospitalisations; and all-cause hospitalisations was estimated using adjusted Poisson regression models. Data from five past RSV seasons (2016-17, 2017-18, 2018-19, 2019-20, and 2022-23), excluding the COVID-19 pandemic period, were used to estimate the number of RSV-related LRTI hospitalisations averted along with its IQR. The number needed to immunise to avoid one case in the 2023-24 season was then estimated from the averted cases. Nirsevimab safety was routinely monitored. The NIRSE-GAL study protocol was registered on ClinicalTrials.gov (NCT06180993), and follow-up of participants is ongoing.

Findings: 9408 (91·7%) of 10 259 eligible infants in the seasonal and catch-up groups received nirsevimab, including 6220 (89·9%) of 6919 in the catch-up group and 3188 (95·4%) of 3340 in the seasonal group. 360 in the high-risk group were offered nirsevimab, 348 (97%) of whom received it. Only infants in the seasonal and catch-up groups were included in analyses to estimate nirsevimab effectiveness and impact because there were too few events in the high-risk group. In the catch-up and seasonal groups combined, 30 (0·3%) of 9408 infants who received nirsevimab and 16 (1·9%) of 851 who did not receive nirsevimab were hospitalised for RSV-related LRTI, corresponding to an effectiveness of 82·0% (95% CI 65·6-90·2). Effectiveness was 86·9% (69·1-94·2) against severe RSV-related LRTI requiring oxygen support, 69·2% (55·9-78·0) against all-cause LRTI hospitalisations, and 66·2% (56·0-73·7) against all-cause hospitalisations. Nirsevimab effectiveness against other endpoints of severe RSV-related LRTI could not be estimated because of too few events. RSV-related LRTI hospitalisations were reduced by 89·8% (IQR 87·5-90·3), and the number needed to immunise to avoid one RSV-related LRTI hospitalisation was 25 (IQR 24-32). No severe adverse events related to nirsevimab were registered.

Interpretation: Nirsevimab substantially reduced infant hospitalisations for RSV-associated LRTI, severe RSV-associated LRTI requiring oxygen, and all-cause LRTI when given in real-world conditions. These findings offer policy makers and health authorities robust, real-world, population-based evidence to guide the development of strategies for RSV prevention.

Funding: Sanofi and AstraZeneca.

Translation: For the Spanish translation of the abstract see Supplementary Materials section.

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1473-3099(24)00215-9DOI Listing

Publication Analysis

Top Keywords

rsv-related lrti
28
lrti hospitalisations
20
nirsevimab effectiveness
16
nirsevimab
15
lrti
13
seasonal group
12
group infants
12
high-risk group
12
infants seasonal
12
severe rsv-related
12

Similar Publications

The dawn of preventing respiratory syncytial virus lower respiratory tract infections in children.

S Afr Med J

October 2024

Department of Critical Care, Wits Donald Gordon Medical Centre and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Article Synopsis
  • - Respiratory syncytial virus (RSV) is the leading cause of lower respiratory infections in children under 1 year, resulting in high hospitalization rates and straining South Africa's healthcare system during its seasonal peaks.
  • - RSV infections in young children can have lasting effects, including chronic respiratory issues like wheezing, asthma, and reduced lung function.
  • - New prevention methods, such as the monoclonal antibody nirsevimab and a maternal RSV vaccine, have shown effectiveness in decreasing hospitalizations, and their implementation could greatly lower RSV-related health risks in South Africa.
View Article and Find Full Text PDF

: Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants. Nirsevimab has demonstrated to be a promising tool for preventing severe RSV disease. Although clinical trials have demonstrated the efficacy of Nirsevimab in preventing severe RSV disease, evidence regarding its performance in real-world clinical settings is still limited due to its recent introduction.

View Article and Find Full Text PDF

Purpose: Several vaccines against respiratory syncytial virus (RSV) are being developed. The objective of this systematic review is to determine the efficacy of these vaccines in preventing RSV disease in adults over 60 years of age, especially regarding severe illness.

Methods: We researched MEDLINE, CENTRAL, Scopus, medRxiv, bioRxiv and ClinicalTrials.

View Article and Find Full Text PDF
Article Synopsis
  • Nirsevimab, a monoclonal antibody, has shown promise in preventing RSV-related lower respiratory tract infections (LRTIs) in clinical trials, but further real-world evaluation is necessary.* -
  • This study analyzed data from Yale New Haven Health System to assess nirsevimab's effectiveness in preventing RSV infections among infants, focusing on factors like disease severity, dosage, and time since vaccination.* -
  • Among 3,090 infants, nirsevimab demonstrated a 68.4% effectiveness overall, with higher effectiveness rates of 80.5% for hospitalizations and 84.6% for severe cases, highlighting its potential in real-world settings.*
View Article and Find Full Text PDF

Comparison of characteristics of children hospitalized for respiratory syncytial virus infection during the pre- and post-COVID-19 eras: a multicenter retrospective study.

BMC Infect Dis

September 2024

Department of Pulmonary and Critical Care Medicine, Yunnan Key Laboratory of Children's Major Disease Research, Yunnan Medical Center for Pediatric Diseases, Kunming Children's Hospital, Kunming Medical University, No. 28, Shulin Street, Xishan District, Kunming, 650034, China.

Article Synopsis
  • Respiratory syncytial virus (RSV) has seen a surge in cases among children following the relaxation of COVID-19 restrictions, prompting a study in Yunnan, China to assess differences in RSV infection characteristics pre- and post-COVID-19.
  • The research included 2553 pediatric patients, analyzing various data, including demographics and clinical symptoms to identify factors associated with severe lower respiratory tract infection (SLRTI) across the two periods.
  • Findings revealed a shift in RSV seasonal patterns and an increase in severe cases, older patient age, and higher clinical and laboratory indicators in post-COVID-19 children compared to those admitted before the pandemic.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!

A PHP Error was encountered

Severity: Notice

Message: fwrite(): Write of 34 bytes failed with errno=28 No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 272

Backtrace:

A PHP Error was encountered

Severity: Warning

Message: session_write_close(): Failed to write session data using user defined save handler. (session.save_path: /var/lib/php/sessions)

Filename: Unknown

Line Number: 0

Backtrace: